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HAIR-AN syndrome (hyperandrogenism, insulin resistance, acanthosis nigricans) is a
subset of the polycystic ovary syndrome, where the patients demonstrate severe insulin
resistance. It is theorized that both genetic and environmental factors, such as obesity,
give rise to the development of HAIR-AN. Diagnosis is primarily clinical, with laboratory
values lending further support. Treatment is aimed at decreasing insulin resistance,
regulating ovulation, and decreasing acne, acanthosis nigricans, and hirsutism.
KEYWORDS: hyperandrogenism, acanthosis nigricans, insulin resistance, United States

INTRODUCTION
HAIR-AN syndrome, which is characterized by hyperandrogenism, insulin resistance, and acanthosis
nigricans, is a subphenotype of the polycystic ovary syndrome. This review will discuss the clinical
presentation, genetic and environmental contributors, diagnosis, and interventions for treatment of this
syndrome.

BACKGROUND
The polycystic ovary syndrome (PCOS) is a disease of infrequent or absent ovulation and
hyperandrogenism. HAIR-AN syndrome is a specific subtype of PCOS characterized by the presence of
severe insulin resistance[1,2]. Approximately 5–10% of females with hyperandrogenism have HAIRAN[3,4] and up to 40% of adolescent patients who present with irregular periods may have HAIR-AN[5].
Most women with HAIR-AN will have clinical symptoms in adolescence; however, diagnosis is often
delayed until adulthood[6,7].
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Clinical Presentation
Clinically, hyperandrogenism associated with HAIR-AN may give rise to acne and slowly progressive
hirsutism. Virilization, which includes temporal balding, voice deepening, rapidly progressive hirsutism,
and clitoromegaly generally suggest more significant androgen exposure and warrant further
evaluation[1,3]. Hirsutism is defined by an increase in the distribution and quantity of terminal hairs (>0.5
cm in length, coarse, usually pigmented) representing a Ferriman and Gallwey score of ≥8[8].
Clinical findings related to insulin resistance are body mass index (BMI) >27 kg/m2, waist to hip ratio
>0.85, waist >100 cm, numerous skin tags (achrochordons), and acanthosis nigricans[9]. Acanthosis
nigricans is velvety, verrucous, hyperpigmented skin found most frequently on the back of the neck,
axillae, and in other skin fold areas (see Fig. 1), and is a known indicator of underlying insulin resistance
and decreased insulin sensitivity. Undiagnosed and untreated insulin resistance is linked to long-term
sequelae, such as coronary artery disease, hyperlipidemia, and Type II diabetes[10].

FIGURE 1.

Insulin Resistance/Hyperinsulinemia
Hyperinsulinemia has been a known component of PCOS since at least 1984[11]. As obesity and body fat
distribution have known effects on glucose metabolism, this contributes to the insulin resistance in HAIRAN[12,13] in obese women. Certainly not all women with HAIR-AN are obese, and when the above
variables are controlled for, insulin resistance is still present[14,15]. In addition, obesity and PCOS have
been found to have a synergistic effect on increasing insulin resistance[14,16]. As insulin resistance
increases, pancreatic β cells increase insulin production to compensate. However, in women with HAIRAN, insulin response to glucose intake is attenuated[17] and defects in β cell function have been
identified[18,19]. Genetic defects, such as mutations of the tyrosine kinase domain of the insulin receptor
gene, have also been suggested in the pathogenesis of HAIR-AN[20,21].

Hyperandrogenism
The prolonged, markedly elevated, insulin levels, which are associated with resistance and decreased
sensitivity, may stimulate the ovary to generate androgens[1,20]. It is theorized that these high levels of
insulin cross-react with insulin-like growth factors, therefore, directly stimulating the overproduction of
ovarian androgens[1,10]. This gives rise to the hyperandrogenism associated with HAIR-AN.

117

Rager and Omar: Androgen Excess Disorder

TheScientificWorldJOURNAL (2006) 6, 116–123

Diagnosis
There is no consistently used “gold standard” of diagnostic testing for HAIR-AN. Diagnosis is often based
on the clinical findings, i.e., evidence of hyperandrogenism (acne, hirsutism) and evidence of insulin
resitance (acanthosis nigricans)[5], but on the other hand, many women with insulin resistance do not have
acanthosis nigricans[9,20]. Multiple laboratory tests have been posited as tools in the diagnosis of HAIRAN, including fasting insulin levels, fasting glucose-to-insulin ratio, glucose challenge testing, and the
euglycemic hyperinsulinemic clamp. These lab values can be helpful; however, the only measure that is
both sensitive and specific is the euglycemic hyperinsulinemic clamp. Regrettably, this test is both
impractically complex and time consuming, and too expensive for the clinic setting[20]. Currently, there is
no solid consensus as to what testing is most beneficial in the evaluation of patients with possible HAIRAN.

Treatment
Likewise, there is no consensus on the “standard of care” for the treatment of HAIR-AN syndrome.
Traditional treatments have included weight loss, oral contraceptive pills, and antiandrogens. Debate
continues regarding treatment with insulin-sensitizing agents, such as metformin.
BMI is known to be directly proportional to insulin resistance[22]. Multiple studies have demonstrated
that obese women with HAIR-AN can have decreased androgens and return of regular ovulation with
weight loss[23,24,25]. As obesity has reached epidemic proportions in the U.S., achieving weight loss in
patients, although not often easy, can have health benefits beyond those directly attributable to HAIR-AN.
There is evidence that weight loss is more easily achieved after the hyperandrogenism and
hyperinsulinemia have improved[26].
Oral contraceptive pills (OCP) are often used to improve menstrual cycle regularity, improve acne, and
decrease hirsutism, and possess the added benefit of prevention of unintended pregnancy[27]. OCP may
suppress the hypothalamic-pituitary-ovarian axis, therefore lowering ovarian steroid/androgen
production[1]. There is no evidence that OCP improve insulin resistance or sensitivity. Some evidence
suggests that OCP should not be used in patients with HAIR-AN, as they might decrease insulin
sensitivity[28]. Recently, Yasmin® (Berlex), an OCP with drospirenone, a spironolactone analog, has been
introduced that may be used in the treatment of the hyperandrogenism associated with HAIR-AN[29].
Antiandrogens, often in conjunction with OCP, may be utilized to decrease acne and hirsutism. These
include spironolactone, GnRH agonists, and flutamide. Spironolactone frequently is used in conjunction
with OCP to target hirsutism. Antiandrogens should not be used in sexually active women who are not on
contraception, as they can have adverse fetal effects.
Treatments aimed at directly increasing insulin sensitivity are the topic of much debate. Insulin
sensitizers that are currently available in the U.S. include metformin, rosiglitazone, and pioglitazone
(troglitazone is no longer available). Metformin is approved by the FDA for treatment of Type II diabetes
mellitus (but not for insulin resistance), and in addition to enhancing peripheral glucose uptake, metformin
increases insulin sensitivity. Metformin is the only insulin sensitizer that is approved for use in those
patients 10–16 years old; however, recent data suggest that rosiglitazone may be beneficial in pediatric
patients[30]. One of the most important clinical outcomes is the improvement in menstrual
regularity/ovulation. Randomized, placebo-controlled trials of metformin and rosiglitazone in obese
patients with PCOS have demonstrated ovulation rates of 30–42%[31,32,33]. In those with PCOS and
severe insulin resistance, ovulation rates have reached 92%[34]. Insulin-sensitizing agents logically are
more likely to induce ovulation in women with higher levels of insulin resistance[32,33,34]. Therefore,
insulin-sensitizing agents are most useful for use in the HAIR-AN subset of PCOS.
Insulin-sensitizing agents also improve hyperandrogenism. Metformin and pioglitazone have been
shown to decrease serum androgens[31,35,36]. The decreased serum androgen levels are likely a direct
consequence of decreased serum insulin levels.
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Two small studies have been carried out in adolescents using metformin and dietary intervention. Both
revealed weight loss and resumption of menses; however, the metformin effects were confounded by the
dietary interventions[37,38]. In addition to the potential for metabolic acidosis and liver damage,
metformin gives rise to gastrointestinal side effects which patients often dislike.

CONCLUSIONS
HAIR-AN syndrome is a disease that manifests in adolescence, yet may have long-reaching consequences
into adulthood. It is important to recognize the symptoms as they present and to treat accordingly.
Although HAIR-AN syndrome was first described over 30 years ago and many advances since been made,
there are still areas which require continuing research: (1) continued insight into the genetic causes and
their relationships with environmental influences, (2) continued development and evaluation of programs
targeting the obesity epidemic, (3) development of more practical sensitive and specific laboratory
diagnostic methods, (4) further investigation of treatment modalities, specifically of the insulin-sensitizing
agents, (5) further investigation of the insulin-sensitizing agents in adolescent populations, and (6) studies
evaluating long-term impact of treatment with insulin-sensitizing agents on the development of Type II
diabetes and cardiovascular disease in patients with HAIR-AN.

KEY POINTS
•
•
•
•
•

HAIR-AN is a subphenotype of polycystic ovary syndrome (PCOS), which differs by the presence
of insulin resistance.
Acanthosis nigricans, acne, hirsutism, and menstrual irregularity should alert the provider to the
possibility their patient has HAIR-AN.
Easily obtained laboratory values may assist with the diagnosis of HAIR-AN, but are not
diagnostic in themselves.
Weight loss, oral contraceptive pills (OCP) use, and antiandrogens may be used in the treatment of
HAIR-AN.
Insulin-sensitizing agents may also be used; however, their use is currently controversial based on
potential side effects and lack of solid long-term data.
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